TG THERAPEUTICS, INC. Net Income
TG THERAPEUTICS, INC. (TGTX) reported Net Income of $7.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-05
- TG THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $7.78M, a 72.40% decline year-over-year.
- TG THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $19.78M, a 290.85% increase year-over-year.
- TG THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $23.06M, a 1.24% decline year-over-year.
- TG THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $390.89M, a 9974.61% increase year-over-year.
- TG THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2013 was -$20.48M.
- TG THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2012 was -$18.07M.
- TG THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2011 was -$853.07K.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed | Net Income (Loss) Attributable to Parent 13 month | Net Income (Loss) Attributable to Parent 15 month | Net Income (Loss) Attributable to Parent 16 month | Net Income (Loss) Attributable to Parent 18 month | Net Income (Loss) Attributable to Parent 19 month | Net Income (Loss) Attributable to Parent 22 month | Net Income (Loss) Attributable to Parent 25 month | Net Income (Loss) Attributable to Parent 28 month | Net Income (Loss) Attributable to Parent 119 month | Net Income (Loss) Attributable to Parent 122 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.78M 10-Q · filed 2026-08-05 | $27.56M 10-Q · filed 2026-08-05 | $50.62M derived: sum of 3 quarters · filed 2026-08-05 | $441.51M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||||
| 2026-03-31 | $19.78M 10-Q · filed 2026-08-05 | $42.84M derived: sum of 2 quarters · filed 2026-08-05 | $433.73M derived: sum of 3 quarters · filed 2026-08-05 | $461.92M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||||
| 2025-12-31 | $23.06M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | $413.95M derived: sum of 2 quarters · filed 2026-04-30 | $442.14M derived: sum of 3 quarters · filed 2026-08-05 | $447.20M DEF 14A · filed 2026-04-30 | $447.18M 10-K · filed 2026-02-27 | |||||||||||||
| 2025-09-30 | $390.89M 10-Q · filed 2025-11-05 | $419.08M derived: sum of 2 quarters · filed 2026-08-05 | $424.14M 10-Q · filed 2025-11-05 | $447.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||||
| 2025-06-30 | $28.19M 10-Q · filed 2026-08-05 | $33.25M 10-Q · filed 2026-08-05 | $56.59M derived: sum of 3 quarters · filed 2026-08-05 | $60.48M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||||
| 2025-03-31 | $5.06M 10-Q · filed 2026-08-05 | $28.41M derived: sum of 2 quarters · filed 2026-08-05 | $32.29M derived: sum of 3 quarters · filed 2026-08-05 | $39.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||||
| 2024-12-31 | $23.35M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | $27.23M derived: sum of 2 quarters · filed 2026-04-30 | $34.11M derived: sum of 3 quarters · filed 2026-04-30 | $23.40M DEF 14A · filed 2026-04-30 | $23.38M 10-K · filed 2025-03-03 | |||||||||||||
| 2024-09-30 | $3.88M 10-Q · filed 2025-11-05 | $10.76M derived: sum of 2 quarters · filed 2025-11-05 | $52.00K 10-Q · filed 2025-11-05 | -$14.34M derived: sum of 4 quarters · filed 2026-04-30 | ||||||||||||||
| 2024-06-30 | $6.88M 10-Q · filed 2025-11-05 | -$3.83M 10-Q · filed 2025-08-08 | -$18.22M derived: sum of 3 quarters · filed 2026-04-30 | $95.71M derived: sum of 4 quarters · filed 2026-04-30 | ||||||||||||||
| 2024-03-31 | -$10.71M 10-Q · filed 2025-11-05 | -$25.09M derived: sum of 2 quarters · filed 2026-04-30 | $88.83M derived: sum of 3 quarters · filed 2026-04-30 | $41.23M derived: sum of 4 quarters · filed 2026-04-30 | ||||||||||||||
| 2023-12-31 | -$14.39M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | $99.54M derived: sum of 2 quarters · filed 2026-04-30 | $51.93M derived: sum of 3 quarters · filed 2026-04-30 | $12.70M DEF 14A · filed 2026-04-30 | $12.67M 10-K · filed 2024-02-29 | |||||||||||||
| 2023-09-30 | $113.93M 10-Q · filed 2024-11-07 | $66.32M derived: sum of 2 quarters · filed 2024-11-07 | $27.09M 10-Q · filed 2024-11-07 | -$25.87M derived: sum of 4 quarters · filed 2026-04-30 | ||||||||||||||
| 2023-06-30 | -$47.61M 10-Q · filed 2024-11-07 | -$86.84M 10-Q · filed 2024-08-09 | -$139.80M derived: sum of 3 quarters · filed 2026-04-30 | -$175.62M derived: sum of 4 quarters · filed 2026-04-30 | ||||||||||||||
| 2023-03-31 | -$39.23M 10-Q · filed 2024-11-07 | -$92.19M derived: sum of 2 quarters · filed 2026-04-30 | -$128.01M derived: sum of 3 quarters · filed 2026-04-30 | -$168.52M derived: sum of 4 quarters · filed 2026-04-30 | ||||||||||||||
| 2022-12-31 | -$52.96M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$88.78M derived: sum of 2 quarters · filed 2026-04-30 | -$129.29M derived: sum of 3 quarters · filed 2026-04-30 | -$198.30M DEF 14A · filed 2026-04-30 | -$198.34M 10-K · filed 2024-02-29 | |||||||||||||
| 2022-09-30 | -$35.82M 10-Q · filed 2023-11-06 | -$76.33M derived: sum of 2 quarters · filed 2023-11-06 | -$145.34M 10-Q · filed 2023-11-06 | |||||||||||||||
| 2022-06-30 | -$40.51M 10-Q · filed 2023-11-06 | -$109.52M derived: sum of 2 quarters · filed 2023-11-06 | ||||||||||||||||
| 2022-03-31 | -$69.01M 10-Q · filed 2023-11-06 | |||||||||||||||||
| 2021-12-31 | -$348.10M DEF 14A · filed 2026-04-30 | -$348.10M 10-K · filed 2024-02-29 | ||||||||||||||||
| 2019-12-31 | -$39.57M 10-K · filed 2020-03-02 | -$101.50M derived: sum of 2 quarters · filed 2020-03-02 | -$137.71M derived: sum of 3 quarters · filed 2020-03-02 | -$172.87M derived: sum of 4 quarters · filed 2020-03-02 | ||||||||||||||
| 2019-09-30 | -$61.93M 10-K · filed 2020-03-02 | -$98.14M derived: sum of 2 quarters · filed 2020-03-02 | -$133.30M derived: sum of 3 quarters · filed 2020-03-02 | -$187.16M derived: sum of 4 quarters · filed 2020-03-02 | ||||||||||||||
| 2019-06-30 | -$36.21M 10-K · filed 2020-03-02 | -$71.37M derived: sum of 2 quarters · filed 2020-03-02 | -$125.23M derived: sum of 3 quarters · filed 2020-03-02 | -$159.18M derived: sum of 4 quarters · filed 2020-03-02 | ||||||||||||||
| 2019-03-31 | -$35.16M 10-K · filed 2020-03-02 | -$89.02M derived: sum of 2 quarters · filed 2020-03-02 | -$122.97M derived: sum of 3 quarters · filed 2020-03-02 | -$167.11M derived: sum of 4 quarters · filed 2020-03-02 | ||||||||||||||
| 2018-12-31 | -$53.86M 10-K · filed 2020-03-02 | -$53.86M 10-K · filed 2019-03-01 | -$87.81M derived: sum of 2 quarters · filed 2020-03-02 | -$131.95M derived: sum of 3 quarters · filed 2020-03-02 | -$173.48M derived: sum of 4 quarters · filed 2020-03-02 | |||||||||||||
| 2018-09-30 | -$33.95M 10-K · filed 2020-03-02 | -$78.09M derived: sum of 2 quarters · filed 2020-03-02 | -$119.62M derived: sum of 3 quarters · filed 2020-03-02 | -$150.48M derived: sum of 4 quarters · filed 2020-03-02 | ||||||||||||||
| 2018-06-30 | -$44.14M 10-K · filed 2020-03-02 | -$85.67M derived: sum of 2 quarters · filed 2020-03-02 | -$116.53M derived: sum of 3 quarters · filed 2020-03-02 | -$148.07M derived: sum of 4 quarters · filed 2020-03-02 | ||||||||||||||
| 2018-03-31 | -$41.53M 10-K · filed 2020-03-02 | -$72.39M derived: sum of 2 quarters · filed 2020-03-02 | -$103.92M derived: sum of 3 quarters · filed 2020-03-02 | -$132.28M derived: sum of 4 quarters · filed 2020-03-02 | ||||||||||||||
| 2017-12-31 | -$30.86M 10-K · filed 2019-03-01 | -$30.86M 10-K · filed 2018-03-15 | -$62.40M derived: sum of 2 quarters · filed 2019-03-01 | -$90.75M derived: sum of 3 quarters · filed 2019-03-01 | -$118.48M derived: sum of 4 quarters · filed 2019-03-01 | |||||||||||||
| 2017-09-30 | -$31.54M 10-K · filed 2019-03-01 | -$31.54M 10-K · filed 2018-03-15 | -$59.89M derived: sum of 2 quarters · filed 2019-03-01 | -$87.62M derived: sum of 3 quarters · filed 2019-03-01 | -$111.29M derived: sum of 4 quarters · filed 2019-03-01 | |||||||||||||
| 2017-06-30 | -$28.35M 10-K · filed 2019-03-01 | -$28.35M 10-K · filed 2018-03-15 | -$56.08M derived: sum of 2 quarters · filed 2019-03-01 | -$79.75M derived: sum of 3 quarters · filed 2019-03-01 | -$104.59M derived: sum of 4 quarters · filed 2019-03-01 | |||||||||||||
| 2017-03-31 | -$27.73M 10-K · filed 2019-03-01 | -$27.73M 10-K · filed 2018-03-15 | -$51.40M derived: sum of 2 quarters · filed 2019-03-01 | -$76.23M derived: sum of 3 quarters · filed 2019-03-01 | -$92.13M derived: sum of 4 quarters · filed 2019-03-01 | |||||||||||||
| 2016-12-31 | -$23.67M 10-K · filed 2018-03-15 | -$48.51M derived: sum of 2 quarters · filed 2018-03-15 | -$64.40M derived: sum of 3 quarters · filed 2018-03-15 | -$78.25M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||||||||
| 2016-09-30 | -$24.83M 10-K · filed 2018-03-15 | -$40.73M derived: sum of 2 quarters · filed 2018-03-15 | -$54.58M derived: sum of 3 quarters · filed 2018-03-15 | -$72.19M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||||||||
| 2016-06-30 | -$15.90M 10-K · filed 2018-03-15 | -$29.75M derived: sum of 2 quarters · filed 2018-03-15 | -$47.36M derived: sum of 3 quarters · filed 2018-03-15 | -$61.02M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||||||||
| 2016-03-31 | -$13.85M 10-K · filed 2018-03-15 | -$31.46M derived: sum of 2 quarters · filed 2018-03-15 | -$45.12M derived: sum of 3 quarters · filed 2018-03-15 | -$62.22M derived: sum of 4 quarters · filed 2018-03-15 | ||||||||||||||
| 2015-12-31 | -$17.61M 10-K · filed 2017-03-16 | -$31.27M derived: sum of 2 quarters · filed 2017-03-16 | -$48.37M derived: sum of 3 quarters · filed 2017-03-16 | -$62.95M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||
| 2015-09-30 | -$13.66M 10-K · filed 2017-03-16 | -$30.76M derived: sum of 2 quarters · filed 2017-03-16 | -$45.34M derived: sum of 3 quarters · filed 2017-03-16 | -$64.13M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||
| 2015-06-30 | -$17.10M 10-K · filed 2017-03-16 | -$31.68M derived: sum of 2 quarters · filed 2017-03-16 | -$50.48M derived: sum of 3 quarters · filed 2017-03-16 | -$67.93M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||
| 2015-03-31 | -$14.58M 10-K · filed 2017-03-16 | -$33.37M derived: sum of 2 quarters · filed 2017-03-16 | -$50.83M derived: sum of 3 quarters · filed 2017-03-16 | -$62.81M derived: sum of 4 quarters · filed 2017-03-16 | ||||||||||||||
| 2014-12-31 | -$18.80M 10-K · filed 2016-03-15 | -$36.25M derived: sum of 2 quarters · filed 2016-03-15 | -$48.23M derived: sum of 3 quarters · filed 2016-03-15 | -$55.78M derived: sum of 4 quarters · filed 2016-03-15 | ||||||||||||||
| 2014-09-30 | -$17.45M 10-K · filed 2016-03-15 | -$29.44M derived: sum of 2 quarters · filed 2016-03-15 | -$36.98M derived: sum of 3 quarters · filed 2016-03-15 | -$42.65M derived: sum of 4 quarters · filed 2016-03-15 | ||||||||||||||
| 2014-06-30 | -$11.99M 10-K · filed 2016-03-15 | -$19.53M derived: sum of 2 quarters · filed 2016-03-15 | -$25.20M derived: sum of 3 quarters · filed 2016-03-15 | -$29.75M derived: sum of 4 quarters · filed 2016-03-15 | ||||||||||||||
| 2014-03-31 | -$7.55M 10-K · filed 2016-03-15 | -$13.21M derived: sum of 2 quarters · filed 2016-03-15 | -$17.77M derived: sum of 3 quarters · filed 2016-03-15 | -$24.35M derived: sum of 4 quarters · filed 2016-03-15 | -$46.95M 10-Q · filed 2014-05-14 | |||||||||||||
| 2013-12-31 | -$5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | -$10.22M derived: sum of 2 quarters · filed 2014-03-07 | -$16.80M derived: sum of 3 quarters · filed 2014-03-07 | -$20.48M 10-K · filed 2014-03-07 | -$39.40M 10-K · filed 2014-03-07 | |||||||||||||
| 2013-09-30 | -$4.56M 10-Q · filed 2013-11-14 | -$11.14M derived: sum of 2 quarters · filed 2013-11-14 | -$14.81M 10-Q · filed 2013-11-14 | -$18.27M derived: sum of 4 quarters · filed 2014-05-14 | -$33.74M 10-Q · filed 2013-11-14 | |||||||||||||
| 2013-06-30 | -$6.58M 10-Q · filed 2013-08-09 | -$10.26M 10-Q · filed 2013-08-09 | -$13.72M derived: sum of 3 quarters · filed 2014-05-14 | -$16.18M derived: sum of 4 quarters · filed 2014-05-14 | -$29.18M 10-Q · filed 2013-08-09 | |||||||||||||
| 2013-03-31 | -$3.67M 10-Q · filed 2014-05-14 | -$7.13M derived: sum of 2 quarters · filed 2014-05-14 | -$9.60M derived: sum of 3 quarters · filed 2014-05-14 | -$11.49M derived: sum of 4 quarters · filed 2014-05-14 | -$22.60M 10-Q · filed 2013-05-14 | |||||||||||||
| 2012-12-31 | -$3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | -$5.92M derived: sum of 2 quarters · filed 2014-03-07 | -$7.82M derived: sum of 3 quarters · filed 2014-03-07 | -$18.07M 10-K · filed 2014-03-07 | -$18.93M 10-K · filed 2013-03-21 | |||||||||||||
| 2012-09-30 | -$2.46M 10-Q · filed 2013-11-14 | -$4.36M derived: sum of 2 quarters · filed 2013-11-14 | -$14.61M 10-Q · filed 2013-11-14 | -$15.16M derived: sum of 4 quarters · filed 2013-11-14 | -$15.47M 10-Q · filed 2012-11-14 | |||||||||||||
| 2012-06-30 | -$1.89M 10-Q · filed 2013-08-09 | -$12.15M 10-Q · filed 2013-08-09 | -$12.69M derived: sum of 3 quarters · filed 2013-08-09 | -$12.72M derived: sum of 4 quarters · filed 2013-08-09 | -$13.00M 10-Q/A · filed 2012-09-07 | |||||||||||||
| 2012-03-31 | -$10.26M 10-Q · filed 2013-05-14 | -$10.80M derived: sum of 2 quarters · filed 2013-05-14 | -$10.83M derived: sum of 3 quarters · filed 2013-05-14 | -$11.11M 10-Q · filed 2012-05-14 | ||||||||||||||
| 2011-12-31 | -$542.36K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21 | -$570.97K derived: sum of 2 quarters · filed 2013-03-21 | -$853.07K derived: sum of 3 quarters · filed 2013-03-21 | -$853.07K 10-K · filed 2013-03-21 | ||||||||||||||
| 2011-09-30 | -$28.61K 10-Q · filed 2012-11-14 | -$551.74K 10-Q · filed 2011-11-14 | -$310.71K derived: sum of 2 quarters · filed 2012-11-14 | -$310.71K 10-Q · filed 2012-11-14 | $298.11K 10-Q · filed 2011-11-14 | -$59.83M 10-Q · filed 2011-11-14 | ||||||||||||
| 2011-06-30 | -$282.11K 10-Q/A · filed 2012-09-07 | -$2.98M 10-Q/A · filed 2011-09-14 | -$282.11K 10-Q/A · filed 2012-09-07 | $849.84K 10-Q/A · filed 2011-09-14 | -$59.28M 10-Q/A · filed 2011-09-14 | |||||||||||||
| 2010-12-31 | $365.23K derived: 10-Q 12 month − 10-Q 9 month · filed 2011-11-14 | $406.48K derived: sum of 2 quarters · filed 2011-11-14 | $2.26M derived: sum of 3 quarters · filed 2011-11-14 | $623.64K 10-Q · filed 2011-11-14 | ||||||||||||||
| 2010-09-30 | $41.25K 10-Q · filed 2011-11-14 | $1.89M derived: sum of 2 quarters · filed 2011-11-14 | $258.41K 10-Q · filed 2011-11-14 | |||||||||||||||
| 2010-06-30 | $1.85M 10-Q/A · filed 2011-09-14 | $217.17K 10-Q/A · filed 2011-09-14 | ||||||||||||||||
| 2009-12-31 | -$2.79M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2008-12-31 | -$4.27M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2007-12-31 | -$12.03M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2006-12-31 | -$9.70M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2005-12-31 | -$19.14M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2004-12-31 | -$5.90M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2003-12-31 | -$5.96M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2002-12-31 | -$1.04M 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2001-12-31 | -$56.80K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |